Tagged with OP

USA Kelly LoBianco, founding director of the Los Angeles County Department of Economic Opportunity, discusses how the agency is driving growth of the region’s life sciences sector. She outlines LA County’s Life Sciences Industry Cluster Strategy and Action Plan, which aims to create 10,000 new industry jobs by 2030 and explains…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lynk Pharmaceuticals and Bao Pharmaceuticals advancing IPO plans on HKEX, Crescent Biopharma entering a US$185M oncology partnership with Kelun-Biotech, and Proviva Therapeutics securing US$30M for its PD-1/IL-2 prodrug. Clinical developments feature Pfizer’s zavegepant nasal spray filing in China, Rhegen’s…

France Pascaline Gervoson, CEO of PiLeJe, a family-owned French nutraceutical company, represents the second generation of leadership following her father’s founding vision in 1992. With 27 years within the organisation and five years as Chief Executive, she oversees a EUR 180 million enterprise specialising in dietary supplements distributed through medical prescription…

Italy Top recent stories from Italian pharma, including Angelini’s EUR 150 million EU collaboration for European health startups, Chiesi’s new deals for enzyme replacement therapies and gene editing, and why Menarini is setting its sights on the US.   European Union teams up with Angelini to funnel €150M to European health…

Europe Cancer is one of Europe’s most urgent health challenges. Responsible for 23 percent of all mortality on the continent, the burden is particularly acute outside the EU5, where access timelines vary dramatically. Countries in Central and Eastern Europe, for example, face some of Europe’s highest cancer mortality rates, largely due…

Spain The latest stories from Spain’s booming healthcare and life science industry. Spain still leads Europe for clinical trial numbers, while a recent meeting between Spanish PM Pedro Sánchez and Roche CEO Thomas Schinecker on a new manufacturing agreement speaks to global pharma’s continued focus on the country. In other news,…

USA John Murphy, III, president & CEO of the Association for Accessible Medicines (AAM) lays out a stark warning: the very medicines that keep the US healthcare system affordable and functioning are at risk. Generics and biosimilars fill nine out of ten prescriptions yet account for a tiny slice of spending,…

Switzerland Switzerland has become a global leader in cutting-edge cancer research, with close collaborations between research institutions, hospitals, and private industry fostering the next generation of globally impactful cancer innovation.   For instance, in Bellinzona, the capital of the Italian-speaking Ticino canton, the Institute of Oncology Research (IOR) is working with…

Switzerland In an uncertain world, Europe – with Switzerland at its heart – is reclaiming its role as an epicentre for testing, scaling, and integrating new medical technologies.   While much of the global narrative around the European life sciences market centres on doom and gloom (access delays for innovative medicines,…

Switzerland With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals – has undoubtedly intensified. Yet the industry continues to wield a super-size effect on the local economy, contributing up to a…

Switzerland For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact geography to achieve unprecedented levels of collaboration across key innovation hubs, rendering it possible to forge strong networks and partnerships…

Global First published in the September/October 2025 edition of ISPOR’s Value & Outcomes Spotlight, David Thompson (Rubidoux Research), Christopher Blanchette (Clinical, Medical and Regulatory Affairs), and Stephanie Earnshaw (Access Strategy Consulting) explore how health economics and outcomes research (HEOR) careers are being reshaped by a fast-changing industry. The authors examine why…